Expertise in
2
conditions

Dr. Manuel R. Borrego

El Paso, TX
Expertise in
2
conditions
Specialties:Family Medicine
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
OverviewInsuranceLocationsClinical Research

Overview

Manuel Borrego is a Family Medicine provider in El Paso, Texas. Dr. Borrego is highly rated in 2 conditions, according to our data. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Obesity in Children, and Hypothyroidism. Dr. Borrego is currently accepting new patients.

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Friday Health
  •  UnitedHealthcare
  •  Humana

Locations

1810 Mcrae Blvd, Suite A, El Paso, TX 79925
915-288-3802
Other Locations
3101 Forney Ln, El Paso, TX 79935
915-317-6033
2600 Idalia Ave, El Paso, TX 79930
915-317-6033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.
Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.
Enrollment Status: Completed
Publish Date: February 22, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

12 Total Publications

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.
Journal: Journal of surgical oncology
Published: April 30, 2024
Similar Doctors
Expertise in
41
conditions
Dr. Martha I. Manquero-Butler
Family Medicine
Expertise in
41
conditions
Dr. Martha I. Manquero-Butler
Family Medicine

Conviva Medical Center Management Of Texas, P.A.

10435 Vista Del Sol Dr, 
El Paso, TX 
 (0.9 mi)
915-591-6229
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Martha Manquero-Butler is a Family Medicine provider in El Paso, Texas. Dr. Manquero-Butler is highly rated in 41 conditions, according to our data. Her top areas of expertise are Hypertensive Heart Disease, Necrosis, Enlarged Liver, and Pediatric Myocarditis. Dr. Manquero-Butler is currently accepting new patients.

Expertise in
5
conditions
Dr. Juan F. Loya
Family Medicine
Expertise in
5
conditions
Dr. Juan F. Loya
Family Medicine

Centro De Salud Familiar La Fe, Inc.

700 S Ochoa St, 
El Paso, TX 
 (7.4 mi)
915-545-4550
Languages Spoken:
English, Elamite, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Juan Loya is a Family Medicine provider in El Paso, Texas. Dr. Loya is highly rated in 5 conditions, according to our data. His top areas of expertise are Osteomyelitis in Children, Type 2 Diabetes (T2D), Cirrhosis, and Xanthoma. Dr. Loya is currently accepting new patients.

Expertise in
3
conditions
Dr. Salvador Molina
Family Medicine | Internal Medicine
Expertise in
3
conditions
Dr. Salvador Molina
Family Medicine | Internal Medicine

Conviva Medical Center Management Of Texas, P.A.

10435 Vista Del Sol Dr, 
El Paso, TX 
 (0.9 mi)
915-591-6229
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Salvador Molina is a Family Medicine specialist and an Internal Medicine provider in El Paso, Texas. Dr. Molina is highly rated in 3 conditions, according to our data. His top areas of expertise are Osteomyelitis, Necrotizing Fasciitis, Osteomyelitis in Children, Myringotomy, and Bone Marrow Aspiration. Dr. Molina is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile